European Radiology:功能CAD-RADS在冠状动脉疾病患者治疗和预后中的价值

2022-06-10 shaosai MedSci原创

冠状动脉CT血管造影(CCTA)是对稳定期胸痛和疑似冠状动脉疾病(CAD)患者进行诊断和治疗计划的一种有效的无创性检查。

冠状动脉CT血管造影(CCTA)是对稳定期胸痛和疑似冠状动脉疾病(CAD)患者进行诊断和治疗计划的一种有效的无创性检查。为了最大限度地发挥CCTA的临床作用,标准化的冠状动脉疾病报告和数据系统(CAD-RADS)的提出有助于临床医生理解成像报告的含义和下一步应该做什么意义重大。然而,CCTA的阳性预测值相对较低,部分病变可能被高估,狭窄程度与下游心肌缺血的相关性较差。因此,解剖学上的CAD-RADS的效用十分有限

CCTA衍生的分数流量储备(FFRCT)是一种无创的影像学检查技术,可以评估整个冠状动脉狭窄的流限制,具有较高的诊断准确性,与有创FFR有良好的相关性,因此对临床决策和预后有很大影响。因此将这一信息整合到解剖学CAD-RADS报告系统中可进一步优化风险分层,并能更好地利用来自解剖学CAD-RADS的信息。然而,到目前为止,很少有研究尝试将解剖学CAD-RADS与FFRCT相结合来指导治疗策略。

近日,发表在European Radiology杂志的一项研究提出了一个新的基于FFRCT的功能性CAD-RADS,并在一个回顾性队列中评估新型功能性CAD-RADS在指导治疗方面的表现,同时与单纯的解剖学CAD-RADS相比,验证功能性CAD-RADS在预测不良预后方面的能力。

本研究提出了一个新的功能性CAD-RADS,并在一个回顾性的多中心队列中评估了功能性CAD-RADS在指导治疗方案指导方面的表现,以实际的临床治疗为参考标准,对所有患者进行CCTA和有创FFR(n = 466)。计算了功能性CAD-RADS相对于解剖性CAD-RADS的净分类改进(NRI)。其次,计算了功能性CAD-RADS在前瞻性双臂队列中的预后价值(566[FFRCT组]与567[CCTA组]),经过1年的随访,用Cox危险比例模型比较了FFRCT组(n = 513)和CCTA组(n = 511)的功能性CAD-RADS以确定有不良预后风险的患者。 

功能性CAD-RADS在指导治疗决策方面表现出优于解剖性CAD-RADS(AUC:0.828 vs. 0.681,p < 0.001),与FFR(AUC:0.828 vs. 0.848,p = 0.253)性能相当。30.0%的患者(n = 140)因功能性CAD-RADS而修改了由解剖学CAD-RADS确定的管理计划(NRI = 0.369,p < 0.001)。功能性CAD-RADS是1年疗效的独立预测因素,一致性指数为0.795,解剖性CAD-RADS的相应数值为0.751。 


图 基于功能性CAD-RADS和解剖学CAD-RADS预后的Kaplan-Meier曲线。功能性CAD-RADS(a)和解剖学CAD-RADS(b)预测的1年累积事件率在功能性CAD-RADS和解剖学CAD-RADS层中有明显差异(均为对数rank p < 0.001)

本研究首次提出了新的功能性CAD-RADS类别,并评估了其在治疗决策中的价值以及预测患者预后中的作用。本研究表明,功能性CAD-RADS所建议的下游患者管理可在临床实践中产生积极的影响,同时对未来风险的分层也有很强大的能力。

 

原文出处:

Chun Xiang Tang,Hong Yan Qiao,Xiao Lei Zhang,et al.Functional CAD-RADS using FFR CT on therapeutic management and prognosis in patients with coronary artery disease.DOI:10.1007/s00330-022-08618-5

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2029555, encodeId=5cc1202955505, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Jan 27 07:53:05 CST 2023, time=2023-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799229, encodeId=7f4f1e99229ad, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri Mar 31 14:53:05 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729608, encodeId=92f51e29608ae, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Apr 03 05:53:05 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793017, encodeId=f4061e9301709, content=<a href='/topic/show?id=6d7e150911e' target=_blank style='color:#2F92EE;'>#RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15091, encryptionId=6d7e150911e, topicName=RADS)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Fri May 12 20:53:05 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252971, encodeId=a59212529e10c, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Jun 08 07:53:05 CST 2022, time=2022-06-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2029555, encodeId=5cc1202955505, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Jan 27 07:53:05 CST 2023, time=2023-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799229, encodeId=7f4f1e99229ad, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri Mar 31 14:53:05 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729608, encodeId=92f51e29608ae, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Apr 03 05:53:05 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793017, encodeId=f4061e9301709, content=<a href='/topic/show?id=6d7e150911e' target=_blank style='color:#2F92EE;'>#RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15091, encryptionId=6d7e150911e, topicName=RADS)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Fri May 12 20:53:05 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252971, encodeId=a59212529e10c, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Jun 08 07:53:05 CST 2022, time=2022-06-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2029555, encodeId=5cc1202955505, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Jan 27 07:53:05 CST 2023, time=2023-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799229, encodeId=7f4f1e99229ad, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri Mar 31 14:53:05 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729608, encodeId=92f51e29608ae, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Apr 03 05:53:05 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793017, encodeId=f4061e9301709, content=<a href='/topic/show?id=6d7e150911e' target=_blank style='color:#2F92EE;'>#RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15091, encryptionId=6d7e150911e, topicName=RADS)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Fri May 12 20:53:05 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252971, encodeId=a59212529e10c, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Jun 08 07:53:05 CST 2022, time=2022-06-08, status=1, ipAttribution=)]
    2023-04-03 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=2029555, encodeId=5cc1202955505, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Jan 27 07:53:05 CST 2023, time=2023-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799229, encodeId=7f4f1e99229ad, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri Mar 31 14:53:05 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729608, encodeId=92f51e29608ae, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Apr 03 05:53:05 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793017, encodeId=f4061e9301709, content=<a href='/topic/show?id=6d7e150911e' target=_blank style='color:#2F92EE;'>#RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15091, encryptionId=6d7e150911e, topicName=RADS)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Fri May 12 20:53:05 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252971, encodeId=a59212529e10c, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Jun 08 07:53:05 CST 2022, time=2022-06-08, status=1, ipAttribution=)]
    2023-05-12 江川靖瑶
  5. [GetPortalCommentsPageByObjectIdResponse(id=2029555, encodeId=5cc1202955505, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Jan 27 07:53:05 CST 2023, time=2023-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799229, encodeId=7f4f1e99229ad, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri Mar 31 14:53:05 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729608, encodeId=92f51e29608ae, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Apr 03 05:53:05 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793017, encodeId=f4061e9301709, content=<a href='/topic/show?id=6d7e150911e' target=_blank style='color:#2F92EE;'>#RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15091, encryptionId=6d7e150911e, topicName=RADS)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Fri May 12 20:53:05 CST 2023, time=2023-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252971, encodeId=a59212529e10c, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Jun 08 07:53:05 CST 2022, time=2022-06-08, status=1, ipAttribution=)]

相关资讯

A&R:系统性硬化症的舒张功能障碍:危险因素和对死亡率的影响

舒张功能障碍与系统性硬化症(SSc)患者死亡风险增加独立相关。应在SSc患者中解决潜在可改变的风险因素,包括冠状动脉疾病和肥胖以降低死亡风险。

Arthritis Rheumatol:类风湿关节炎与冠状动脉疾病和卒中风险的遗传易感性

该研究发现类风湿性关节炎的遗传倾向与冠心病和脑出血的风险增加相关,而这可能是由CRP介导的。应积极监测和管理类风湿性关节炎患者升高的心血管风险,这可能包括抑制全身炎症。

李悦:如何处理冠状动脉难治性血栓

临床上针对冠状动脉难治性血栓患者,要尽量遵循“多取出,少植入”的原则,若盲目植入支架,很容易造成慢血流,甚至无复流情况发生,严重影响患者的预后。

中国50万人研究:每多吃2两粗粮,糖尿病与中风风险分别下降14%和13%!so easy!

J Nutr.:粗粮摄入量与心脏代谢疾病风险:一项中国成年人的前瞻性队列研究

Cardiovasc Diabetol:冠心病对糖尿病患者左心室功能的不良影响

冠状动脉疾病对2型糖尿病患者的左心室收缩和舒张功能具有附加的有害影响。

JAMA Cardiol:高密度脂蛋白胆固醇水平过高,冠状动脉疾病患者死亡风险增加

非常高的HDL-C水平与冠状动脉疾病患者较高的死亡风险相关